The renal effects of SGLT2 inhibitors and a mini-review of the literature.

about

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Epithelial Organization: The Gut and Beyond.Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.

P2860

Q33696974-D9C885AC-066A-421F-AE42-8AF64E2540A1 Q47795925-CEA539ED-E7DD-4886-8700-F244DB8B092F Q48015498-228C11E1-971E-4C93-9CBC-0D8A1F16E0C6

P2860

The renal effects of SGLT2 inhibitors and a mini-review of the literature.

Item

http://www.wikidata.org/entity/Q37632127

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

The renal effects of SGLT2 inhibitors and a mini-review of the literature.

@en

The renal effects of SGLT2 inhibitors and a mini-review of the literature.

@nl

type

Item

label

The renal effects of SGLT2 inhibitors and a mini-review of the literature.

@en

The renal effects of SGLT2 inhibitors and a mini-review of the literature.

@nl

prefLabel

The renal effects of SGLT2 inhibitors and a mini-review of the literature.

@en

The renal effects of SGLT2 inhibitors and a mini-review of the literature.

@nl

P1476

The renal effects of SGLT2 inhibitors and a mini-review of the literature.

@en

P2093

John Doupis

http://www.w3.org/2001/XMLSchema#string

Spyridoula Glykofridi

http://www.w3.org/2001/XMLSchema#string

Vasileios Andrianesis

http://www.w3.org/2001/XMLSchema#string

P2860

The fundamental drivers of the obesity epidemic

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

SGLT2 Inhibitors May Predispose to Ketoacidosis

The sodium/glucose cotransport family SLC5

Active sugar transport in health and disease

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar

The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?

Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.

P304

212-228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2042018816676239

http://www.w3.org/2001/XMLSchema#string

P433

5-6

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28203358

http://www.w3.org/2001/XMLSchema#string

P932

5298360

http://www.w3.org/2001/XMLSchema#string

The renal effects of SGLT2 inhibitors and a mini-review of the literature.

about

P2860

P2860

The renal effects of SGLT2 inhibitors and a mini-review of the literature.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932